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One of the emerging themes in cancer biology is the depen-
dence of cancer subtypes on certain signaling pathways for con-
tinued tumor growth. For example, mutations that activate the 
Hedgehog (Hh) signaling pathway drive growth of a variety of 
cancers including basal cell carcinomas (BCCs) and medullo-
blastomas, along with pancreatic, prostate, and small cell lung 
cancer that account for up to 25% of all human cancer deaths 
(Epstein, 2008). BCCs are the most prevalent cancer in the 
world, and nearly half of all US citizens are likely to develop 
this cancer before retirement (National Cancer Institute, 2010). 
Twenty years of extensive research identifying Hh pathway 
components and their functional roles recently culminated in 
the newly FDA approved Hh pathway antagonist vismodegib 
(Erivedge; Genentech/Roche) for the treatment of locally advanced 
or metastatic BCCs. Although vismodegib and other Smo in-
hibitors appear effective, treatment-driven tumor evolution has 
resulted in the outgrowth of tumor cell variants resistant to the 
drug. This rapid tumor evolution during treatment highlights the 
continued need to understand how tumors circumvent pathway 
blockade and identify new therapeutic targets for treating 
Hh-dependent cancers. In this article, we summarize the suc-
cessful development of Hh pathway inhibitors and highlight 
promising areas for the development of next generation drug 
antagonists for Hh-dependent cancers.
A compelling connection to human cancer
Hh signaling is essential for development of all vertebrates and 
drives proliferation, migration, and differentiation of progeni-
tor cells to pattern organ development (Varjosalo and Taipale, 
2008). Despite the critical nature of Hh signaling, how Hh me-
diates tumor proliferation remains poorly understood. Hh path-
way activation begins when the Hh ligand binds to and inhibits 
the transmembrane receptor Patched1 (Ptch1), allowing the sig-
nal transducer Smoothened (Smo) to activate Gli transcription 
factors and amplify Hh target gene expression. So far, all of 
the nuclear events ascribed to Hh occur through the Gli tran-
scription factors, with Gli1 acting predominantly as an activator, 
Gli3 acting predominantly a repressor, and Gli2 possessing both 
repressive and activator functions.
Although most of the major components of the Hh path-
way have been known from three decades of work in Drosophila 
melanogaster, the role of the primary cilium, a microtubule-based 
organelle, as a vertebrate-specific regulator of the pathway has 
been appreciated only recently (Huangfu et al., 2003). Abnor-
malities within ciliary components lead to a variety of devel-
opmental defects and cancer predisposition syndromes called 
“ciliopathies,” which include Hh-specific phenotypes (Hildebrandt 
et al., 2011; Hui and Angers, 2011). The primary cilium is 
necessary to amplify Hh signal in vertebrates, in addition to 
regulating Gli processing and activity (Hui and Angers, 
2011). In the absence of Hh ligand, ciliary Ptch1 suppresses 
Smo activity and entry into the cilium, allowing the negative 
regulator Suppressor of Fused (Sufu) to inhibit Gli activity 
(Fig. 1 A). Ptch1 transiently exits the primary cilium after in-
activation by Hh ligand, allowing entry of active Smo into the 
cilium that binds to and inhibits Sufu, resulting in Gli transcrip-
tional activity (Fig. 1 B). Ciliary components actively transduce 
Hh signal, and mutations that disrupt intraflagellar traffick-
ing, such as ift25, activate the pathway through inappropriate 
accumulation of Smo and Ptch1 along the ciliary shaft and loss 
of Gli at the ciliary tip (Keady et al., 2012). Moreover, primary 
cilia regulate Gli processing and inhibition through SuFu, which 
determines the level of pathway activation (Humke et al., 2010; 
Tukachinsky et al., 2010).
Dependence of basal cell carcinomas and medulloblas-
tomas on the Hedgehog pathway provides an opportu-
nity for targeted or “personalized” therapy. The recent 
effectiveness and FDA approval of the first Smoothened 
inhibitors validates this class of agents, but has revealed 
drug-resistant tumor variants that bypass Smoothened 
inhibition. Here, we summarize the effectiveness of 
Hedgehog pathway inhibitors and highlight promising 
areas for the development of next generation drug antago-
nists for Hedgehog-dependent cancers.
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potently inhibits Smo (Chen et al., 2002b) and has efficacy 
against Hh-dependent tumors. Independent in vitro screens by 
several groups led to the discovery of other Smo antagonists 
with distinct molecular structure, with one, vismodegib, recently 
approved for clinical use (Chen et al., 2002a; Weiss and Korn, 
2012). Vismodegib was identified from a small molecule screen 
for Hh pathway antagonists and achieved its final clinical form 
after chemical optimization for improved solubility, metabolic 
stability, and biodistribution (Robarge et al., 2009).
Clinical trials using Smo antagonists in patients reveal 
heterogeneous responses from BCCs in different patient groups. 
Patients with basal cell nevus syndrome (BCNS) carry a Ptch1 
mutation that predisposes them to develop hundreds of BCCs 
with relatively little sun exposure. Despite the high tumor bur-
den, Smo blockade using vismodegib appears effective with a 
surprising 100% (38 of 38) response rate in patients (Tang et al., 
2012). Although many lesions existed on each patient, no 
Overwhelming data exists for the dependence of BCC 
and medulloblastoma growth on Hh pathway activation. For 
instance, BCCs, which are invasive epithelial tumors, originate 
from activating mutations in the Hh pathway in progenitor cells 
of the interfollicular epidermis and hair follicle. They retain 
basal keratinocyte histology, and invade as either branching 
or nest-like nodular structures. Mutations that inappropriately 
express SHH, inhibit Patched1, or activate Smo (Fig. 1 C) com-
prise the bulk of BCC cases (Epstein, 2008; Gomez-Ospina 
et al., 2012). Induction of Hh target genes in human skin grafts 
also results in BCC-like changes (Callahan et al., 2004), which 
indicates that pathway activation is sufficient for tumorigenesis 
and provides compelling therapeutic targets in these tumors.
The first Smo inhibitor: How effective is it?
The first clues that the Hh pathway could be targeted came from 
the observation that the plant-derived compound cyclopamine 
Figure 1. Hh pathway activation, inhibition, and mechanisms of drug resistance. (A) Diagram of inactive Hh pathway in vertebrates. (B) Hh ligand acti-
vates signaling by binding and inhibiting Ptch1, allowing Smo to suppress Sufu and activate Gli transcription factors to turn on Hh target genes. (C) Common 
pathway-dependent genetic mutations that lead to Hh-dependent tumors include Ptch1 inactivation, Smo activation, or inappropriate SHH expression. 
(D) Smo antagonists such as vismodegib suppress Hh activation to prevent tumor growth. (E) Genetic escape pathways that evolve during Smo antagonist 
treatment include Smo point mutations that prevent Smo–drug interaction or (F) Gli target gene amplification of Gli2 or Ccnd1. (G) Compensatory escape 
pathways that have evolved include inappropriate activation of S6K1 that prevents Sufu inhibition of Gli and (H) PI3K pathway up-regulation leading to 
inappropriate Gli activity through currently unknown mechanisms.
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common escape mechanisms may help prescreen patients to 
determine which targeted therapy or combination of targeted 
therapies is most likely to be effective.
Pathway-dependent genetic alterations discovered in re-
sistant tumors from patients and animal models directly affect 
Hh pathway members. Initial studies in medulloblastoma sug-
gest that vismodegib resistance stems from genetic alterations 
at the level of, or downstream from, Smo. Resistance can origi-
nate from Smo point mutations that ablate Smo–drug inter-
action while maintaining Hh pathway activation (Yauch et al., 
2009). These mutations occur in the ligand-binding pocket of 
Smo (Fig. 1 E). Other genetic alterations that lead to resistance 
come from gene duplications of Gli2 or Hh target gene cyclin 
D1 (Fig. 1 F) that bypass the requirement of Smo to inappropri-
ately maintain or increase Gli target gene induction (Buonamici 
et al., 2010; Dijkgraaf et al., 2011). These mutations promote 
high Hh pathway activation in the presence of Smo antagonists 
and mediate resistant tumor growth.
Compensatory alterations outside of the canonical Hh 
pathway have also been found that mediate tumor resistance. 
A compensatory alteration is one where elevated Hh activation 
occurs in the absence of direct genetic mutation or copy number 
variation of Hh pathway members, and is epigenetic in nature. 
One example is the up-regulation of the phosphoinositide 3-
kinase (PI3K) pathway (Buonamici et al., 2010). PI3K and its 
downstream effectors were enriched in resistant versus sensitive 
medulloblastoma tumors, which suggests that PI3K signaling 
may in part promote tumor resistance by up-regulating Hh path-
way activation (Fig. 1 H). As PI3K signaling can potentiate Gli-
dependent transcription induced by low levels of Hh (Riobó 
et al., 2006), PI3K signaling may work best to promote tumor 
resistance when Smo antagonists suppress Hh pathway activa-
tion. In support of this hypothesis, PI3K or PI3K-mTOR inhibi-
tors in combination with a Smo antagonist can delay tumor 
resistance (Buonamici et al., 2010).
Similarly, in esophageal cancers resistant to Smo inhibi-
tors, the activity of mTOR pathway component S6 kinase 1 
(S6K1) was found to be elevated (Wang et al., 2012). S6K1 
phosphorylates Gli1, releasing Gli1 from Sufu inhibition to 
activate Gli-dependent transcription (Fig. 1 G). S6K1 renders 
Gli1-expressing tumors partially Smo independent, as inhibition 
from Sufu is derepressed. Interestingly, S6K1 is inappropriately 
activated in esophageal adenocarcinoma and some medullo-
blastomas (Dijkgraaf et al., 2011; Wang et al., 2012), providing 
a partial explanation for drug resistance.
disease progression or acquired resistance developed during the 
treatment period (mean of 8 mo), revealing a particularly sensi-
tive tumor population with a slow rate of evolution. Vismodegib 
treatment appeared both tumoricidal and tumoristatic, as many 
of the tumors regrew with cessation of the drug.
In contrast, treatment of more invasive tumors demon-
strates a lower response rate. Phase I trials treating metastatic 
or locally advanced BCC found that only about half (19 of 33 
patients) displayed tumor regression (Von Hoff et al., 2009; 
LoRusso et al., 2011), despite having a similar BCC histology 
to the discussed BCNS patients (Fig. 2). Likewise, patients in 
a phase II clinical trial showed a response rate of 30% (10 of 33) 
in metastatic and 43% (27 of 63) in locally advanced BCCs 
(Sekulic et al., 2012). Finally, more invasive solid tumors such 
as small cell lung or pancreatic cancers demonstrate little or 
no responsiveness in early phase clinical trials (LoRusso et al., 
2011), despite an inhibition of Hh pathway activity in uninvolved 
skin from the same patient. Although larger Hh-dependent tumor 
studies need to be performed, early evidence supports the idea 
that more invasive tumor subtypes exhibit a much greater ability 
to resist Smo blockade.
The rate of acquired resistance represents an alternative 
measure of tumor evolution. Although one-third of advanced 
BCC tumors initially respond, persistent vismodegib therapy 
leads to significant secondary resistance (Chang and Oro, 2012). 
Of the 28 patients continuously treated with Smo inhibitor, 21% 
developed at least one tumor regrowth while on the drug, with 
the mean time to detected regrowth at 56 wk (Fig. 2). These 
data indicate that more aggressive tumors display higher initial 
resistance and are more capable of evolving drug-independent 
growth characteristics. One possibility for the differential re-
sponse between tumors is that syndromic BCCs are somehow 
different from sporadic BCCs. Arguing against this idea is the 
fact that 6 of the 28 patients were BCNS patients that developed 
locally advanced disease, and 3 of these 6 patients acquired 
drug resistance during treatment. It is possible that advanced 
BCCs have higher mutation rates or more tumor cells, leading 
to a higher chance of resistant mutations that contribute to the 
ability of the tumor to evolve resistance.
Pathway and compensatory tumor 
evolution in treated patients
Predicting tumor response to targeted therapies requires an un-
derstanding of the how mutations are generated and the evo-
lutionary mechanisms used to bypass treatment. Many recent 
excellent reviews exist about the molecular basis of the muta-
tor phenotype, where alterations in a mutator gene dramatically 
increase mutation rates at other loci (Loeb, 2011). This topic 
will not be discussed further here. However, a key question in 
drug-induced tumor resistance is: how do tumors bypass the 
Smo blockade? Advanced tumors can evolve resistance through 
pathway-dependent genetic mechanisms or through compensa-
tory adaptation. Recent data indicate that pathway and compen-
satory intratumor heterogeneity exists at the time of diagnosis. 
Drug-resistant clones, initially present in low numbers, become 
the dominant clone as they gain growth advantage in the treated 
tumor (Diaz et al., 2012; Misale et al., 2012). Understanding 
Figure 2. The Smo antagonist vismodegib is an effective BCC therapy.  
(A) Multiple untreated, but biopsy proven, BCC tumors in an individual 
with a genetic syndrome leading to Shh overexpression. (B) Vismodegib-
treated tumors shrink, but several resistant tumors remain after 1 yr of drug 
treatment. Image courtesy of A.L.S. Chang.
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Racing against tumor evolution
Developing effective targeted therapies to dispatch tumors 
before they evolve resistance requires knowledge of available 
escape pathways. This is especially critical given that resistant 
clones are likely present in small numbers at the time of treat-
ment initiation. Given the pathway and compensatory altera-
tions in Hh-dependent tumors thus far, dual targeting of the most 
downstream component of the pathway, and the compensatory 
pathways, will likely generate optimal therapies. Gli transcrip-
tion factors ultimately transduce the signal from the Hh ligand; 
moreover, escape pathways that bypass Smo still activate Gli. 
Targeting Gli directly or the signaling components that activate 
Gli could prove quite successful as the next level of therapy.
Several Gli inhibitors have been identified that have 
impressive efficacy. Through a screen of the National Insti-
tutes of Health compound library, molecules such as GANT58 
and GANT61 were found to block Gli transcriptional activity 
(Lauth et al., 2007). These drugs inhibit Hh signaling with a 
similar IC50 to cyclopamine and suppress Gli1-positive human 
prostate cancer xenografts. Moreover, similar screens using a 
library of previously FDA-approved drugs identified arsenic tri-
oxide (ATO) as a Gli antagonist (Kim et al., 2010). ATO blocks 
accumulation of Gli2 to primary cilia, with longer incubation 
times reducing steady-state Gli2 protein levels, resulting in sup-
pression of medulloblastoma growth in mouse models. As ATO 
is already in clinical use for acute promyelocytic leukemia, this 
may be a useful therapy for resistant BCCs in the near future.
Identifying and targeting modulators of Gli activity may 
also show promise in preventing or treating resistant tumors. 
New pathways that regulate Gli such as the aforementioned 
S6K1 may hold the key to delay tumor resistance. Because 
S6K1 appears to regulate Gli1 activity downstream of mTOR, 
and Smo inhibitors regulate Gli activity and nuclear localiza-
tion, combination therapy may prevent tumor cells containing 
this compensatory alteration from growing. Indeed, in vitro data 
from esophageal adenocarcinoma xenografts suggest that com-
bination therapy with mTOR inhibitors and vismodegib work 
synergistically (Wang et al., 2012). These data provide strong 
preclinical support for the use of combined therapy to delay 
growth of Smo antagonist–resistant tumors.
The blueprint to develop the first Hh pathway inhibitors 
came from impressive efforts from the Hh and cancer communi-
ties, beginning with identification of Hh pathway components and 
their roles in cancer and continuing with intense screening and me-
dicinal chemistry that refined drug targets for optimal human use. 
The challenge for the future is to better understand common path-
way-dependent genetic and compensatory escape pathways that 
evolve from clonal populations within tumors and design combi-
nation therapies to block them before further evolution takes place. 
Through improved genomics, cell biology, and medicinal chemis-
try, this may be a race medical research can win.
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